TEL AVIV, Israel, May 24, 2017 /PRNewswire/ -- Therapix Biosciences
Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage
pharmaceutical Company specializing in the development of
cannabinoid-based drugs, today announced that following the
mutual decision of the Company's Board of Directors and Dr. Elran
Haber, the Company's Chief Executive Officer, Dr. Haber will step
down from his position as Chief Executive Officer to pursue other
professional opportunities. The Company's Board of Directors is
undertaking a search to identify a permanent, U.S. based Chief
Executive Officer. Dr. Haber will continue to serve in his position
while the search for a new Chief Executive Officer takes place.
"On behalf of the Therapix Board of Directors, I would like to
thank Dr. Haber for his extraordinary service to our Company.
Therapix made considerable progress under his leadership, including
a successful U.S. initial public offering, and significant
advancement in the Company's clinical development programs,"
commented Dr. Ascher
Shmulewitz, Chairman of the Board of Therapix.
"It has been a sincere pleasure to lead Therapix and I am proud
of all we accomplished. I am thankful for the opportunity to have
worked with a world-class team of professionals. I believe
that the Company has reached the point at which it will benefit
from U.S.-based leadership," said Dr. Haber.
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists, focused on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in two internal drug development programs based on repurposing an
FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets
to the treatment of Tourette's syndrome; and THX-ULD01 targets the
high-value and under-served market of mild cognitive impairments.
Please visit our website for more information at
www.therapixbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements about the
Company's expectations, beliefs, and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss our search for a U.S. based Chief Executive
Officer. These forward-looking statements involve certain risks and
uncertainties, including, among others, risks that could cause the
Company's results to differ materially from those expected by
Company management or otherwise described in or implied by the
statements in this press release. Any forward-looking statement in
this press release speaks only as of the date of this press
release. The Company undertakes no obligation to publicly update or
review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by any applicable securities laws. More detailed
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in Therapix
Biosciences Ltd.'s annual report on Form 20-F dated May 1, 2017 filed with the SEC, which is
available on the SEC's website, www.sec.gov.
For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences,
josh@therapixbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/therapix-biosciences-announces-ceo-change-300463587.html
SOURCE Therapix Biosciences Ltd